A prospective phase 2 study of combination epigenetic therapy against relapsed/refractory peripheral Tcell lymphoma.

Abstract

Peripheral Tcell lymphomas (PTCLs) are prototypical epigenetic malignancies with invariably poor prognoses. Novel and effective therapeutic strategies are needed to improve clinical outcomes, particularly in relapsed/refractory patients. We conducted a multicenter phase 2 study to evaluate the therapeutic efficacy of azacitidine and chidamide, alone or in combination with gemcitabine and oxaliplatin (GemOx), in patients with relapsed/refractory PTCLs (registration number: ChiCTR2000037232). The primary endpoint was the best overall response rate. As of May 1st, 2024, thirty patients were evaluable for efficacy and toxicity. The best overall response rate was 53.3%, meeting its primary endpoint. Among the patients with angioimmunoblastic Tcell lymphoma (AITL; N= 19), a numerically higher response rate was observed, regardless of whether chemotherapy was combined, compared to patients with non-AITL. After a median follow-up of 36.6months, median progression-free survival and overall survival were 7.1 and 8.7months, respectively. Patients with AITL who received combination chemotherapy (N= 12) achieved the most promising response rates (overall response rate, 91.7%; complete remission rate, 66.7%) and survival outcomes (median progression-free survival, 17.2months; median overall survival, 38.8months). The most common grade 3-4 toxicities were neutropenia (40.0%) and thrombocytopenia (30.0%). The combination of epigenetic therapy with GemOx was well tolerated and highly effective in patients with relapsed/refractory PTCLs. Patients with AITL, in particular, may benefit more from this combination treatment and should be the focus of future studies. This work was funded by the Natural Science Foundation of Jiangsu Province (BK20232039).